Back to News
Research
Montana’s plan to become an experimental medical hub just pushed forward
MIT Tech Review·July 30, 2026·1 min read
AI Summary
Montana has implemented a streamlined process for biotech companies to sell experimental drugs to consumers, with just preliminary testing required. Companies can apply for approval from a new review board for a fee of $12,500 after conducting initial trials with as few as 10 healthy participants.
From the source
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…
The full text couldn't be loaded here (the source may require a subscription).
View original at MIT Tech ReviewKeep reading
The Download: tricking LLMs, and reviving geothermal plantsMIT Tech Review · 12h agoA fundamental flaw leaves LLMs strikingly vulnerable to attackMIT Tech Review · 14h agoHow an overlooked geothermal plant got a second chanceMIT Tech Review · 1d agoThe Download: a chip talent battle, and deflating AI hypeMIT Tech Review · 1d ago
Was this useful?